NASDAQ:PNT POINT Biopharma Global (PNT) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free PNT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$12.49▼$12.5150-Day Range$12.45▼$14.2352-Week Range$6.57▼$14.35Volume3.29 million shsAverage Volume1.44 million shsMarket Capitalization$1.33 billionP/E Ratio13.89Dividend YieldN/APrice Target$12.80 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media Get POINT Biopharma Global alerts: Email Address POINT Biopharma Global MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside2.4% Upside$12.80 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.69) to ($0.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.17 out of 5 starsMedical Sector918th out of 939 stocksPharmaceutical Preparations Industry419th out of 429 stocks 1.0 Analyst's Opinion Consensus RatingPOINT Biopharma Global has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 10 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.80, POINT Biopharma Global has a forecasted upside of 2.4% from its current price of $12.50.Amount of Analyst CoveragePOINT Biopharma Global has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for PNT. Previous Next 0.0 Dividend Strength Dividend YieldPOINT Biopharma Global does not currently pay a dividend.Dividend GrowthPOINT Biopharma Global does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PNT. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for PNT on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, POINT Biopharma Global insiders have not sold or bought any company stock.Percentage Held by Insiders16.00% of the stock of POINT Biopharma Global is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions59.53% of the stock of POINT Biopharma Global is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for POINT Biopharma Global are expected to grow in the coming year, from ($0.69) to ($0.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of POINT Biopharma Global is 13.89, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.68.Price to Earnings Ratio vs. SectorThe P/E ratio of POINT Biopharma Global is 13.89, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 188.96.Price to Book Value per Share RatioPOINT Biopharma Global has a P/B Ratio of 2.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About POINT Biopharma Global Stock (NASDAQ:PNT)POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.Read More Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) PNT Stock News HeadlinesJanuary 8, 2024 | businesswire.comDomain Therapeutics Strengthens Leadership Team to Spearhead Global Development and North American Expansion as the Leading GPCR Immuno-Oncology CompanyDecember 27, 2023 | finance.yahoo.comLilly Completes Acquisition of POINT BiopharmaMarch 28, 2024 | Behind the Markets (Ad)The AI Defense Stock Set to SoarTo protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.December 22, 2023 | markets.businessinsider.comPOINT Biopharma Global Rating Adjustment: Hold Recommendation Following Shareholder Dynamics and Acquisition ProspectsDecember 22, 2023 | msn.comBrookline Capital Downgrades POINT Biopharma Global (PNT)December 22, 2023 | benzinga.comPOINT Biopharma Global Stock (NASDAQ:PNT), Guidance and ForecastDecember 18, 2023 | msn.comLilly extends tender offer for POINT Biopharma to Dec. 22December 18, 2023 | seekingalpha.comWhy POINT Biopharma Global Is At Least A Hold On Disappointing ReadoutMarch 28, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…December 18, 2023 | markets.businessinsider.comLantheus Holdings And POINT Biopharma Announced Lu-PNT2002 Phase 3 SPLASH Study ResultsDecember 8, 2023 | msn.comPOINT Biopharma Global Inc. (PNT) Upgraded to Buy: Here's What You Should KnowDecember 4, 2023 | markets.businessinsider.comLilly Says Tender Offer Expiration Extended Related To POINT Biopharma AcquisitionNovember 30, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: POINT Biopharma Global (PNT), Regeneron (REGN) and Incyte (INCY)November 17, 2023 | markets.businessinsider.comHold Rating on POINT Biopharma Global: An Assessment of Acquisition Offer, Pipeline Updates, and Financial StabilityNovember 17, 2023 | finance.yahoo.comLilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023November 15, 2023 | benzinga.comPOINT Biopharma Global Stock (NASDAQ:PNT) Earnings Dates and Earning CallsNovember 15, 2023 | markets.businessinsider.comLilly Receives NRC Consent In Connection With Proposed Acquisition Of POINT BiopharmaNovember 15, 2023 | markets.businessinsider.comPiper Sandler Keeps Their Hold Rating on POINT Biopharma Global (PNT)November 14, 2023 | benzinga.comPOINT Biopharma Global (PNT) News: Johnson Fistel Investigates Proposed Sale; Is $12.50 a Fair Price?November 14, 2023 | seekingalpha.comPOINT Biopharma Global: Why The Market Believes That A Second Bidder May EmergeNovember 13, 2023 | benzinga.comRecap: POINT Biopharma Global Q3 EarningsNovember 13, 2023 | markets.businessinsider.comPOINT Biopharma Reports Loss In Q3, Flat With Last Year, A Week After Lilly Agreed To Acquire ItNovember 13, 2023 | finance.yahoo.comPOINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business HighlightsNovember 8, 2023 | msn.comEli Lilly extends expiration of tender offer to acquire Point BiopharmaNovember 8, 2023 | markets.businessinsider.comLilly Extends Tender Offer For POINT Biopharma Global Until Nov. 16November 8, 2023 | finance.yahoo.comLilly Announces Extension of Tender Offer to Acquire POINT BiopharmaNovember 6, 2023 | msn.comPoint Biopharma quickly gains as big holder comes out against Eli Lilly dealSee More Headlines Receive PNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for POINT Biopharma Global and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PNT CUSIPN/A CIK1811764 Webwww.pointbiopharma.com Phone64-7812-2417FaxN/AEmployees129Year FoundedN/APrice Target and Rating Average Stock Price Target$12.80 High Stock Price Target$14.00 Low Stock Price Target$12.50 Potential Upside/Downside+2.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$0.90 Trailing P/E Ratio13.89 Forward P/E RatioN/A P/E GrowthN/ANet Income$98.29 million Net Margins39.62% Pretax Margin52.16% Return on Equity21.10% Return on Assets18.28% Debt Debt-to-Equity Ratio0.01 Current Ratio9.14 Quick Ratio9.14 Sales & Book Value Annual Sales$226.58 million Price / Sales5.88 Cash Flow$0.94 per share Price / Cash Flow13.31 Book Value$4.68 per share Price / Book2.67Miscellaneous Outstanding Shares106,570,000Free Float89,518,000Market Cap$1.33 billion OptionableOptionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Allan Charles Silber (Age 73)Executive Chairman Comp: $1.02MDr. Joe A. McCann Ph.D. (Age 45)CEO & Director Comp: $1.06MDr. Neil E. Fleshner FRCSC (Age 59)M.D., M.PH, Chief Medical Officer & Director Comp: $318.49kMs. Jessica D. Jensen M.P.H. (Age 43)Executive Vice President of Clinical Development Comp: $816.17kMr. Bill Demers B.B.A. (Age 64)F.C.A., FCPA, CFO & Corporate Secretary Comp: $78.26kMs. Justyna Kelly M.Sc. (Age 38)Chief Operating Officer Ms. Jazz BraichSVP of People & CultureMr. Ari ShomairVP of Corporate Affairs & Chief of StaffDr. Myra Rosario Herle Ph.D.R.Ph., Executive Vice President of Regulatory AffairsDr. Matthew P. Vincent J.D.Ph.D., Senior Vice President of Business DevelopmentMore ExecutivesKey CompetitorsProthenaNASDAQ:PRTAMannKindNASDAQ:MNKDPacira BioSciencesNASDAQ:PCRXAbCellera BiologicsNASDAQ:ABCLXencorNASDAQ:XNCRView All CompetitorsInstitutional OwnershipPerceptive Advisors LLCSold 800,000 shares on 2/26/2024Ownership: 0.000%Clear Street Markets LLCBought 71,600 shares on 2/15/2024Ownership: 0.000%Citadel Advisors LLCSold 900 shares on 2/15/2024Ownership: 0.000%View All Institutional Transactions PNT Stock Analysis - Frequently Asked Questions Should I buy or sell POINT Biopharma Global stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for POINT Biopharma Global in the last twelve months. There are currently 10 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PNT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PNT, but not buy additional shares or sell existing shares. View PNT analyst ratings or view top-rated stocks. What is POINT Biopharma Global's stock price target for 2024? 10 brokerages have issued 12-month price objectives for POINT Biopharma Global's stock. Their PNT share price targets range from $12.50 to $14.00. On average, they expect the company's stock price to reach $12.80 in the next year. This suggests a possible upside of 2.4% from the stock's current price. View analysts price targets for PNT or view top-rated stocks among Wall Street analysts. How were POINT Biopharma Global's earnings last quarter? POINT Biopharma Global Inc. (NASDAQ:PNT) announced its quarterly earnings results on Monday, November, 13th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.07. The company earned $2.79 million during the quarter, compared to the consensus estimate of $8 million. POINT Biopharma Global had a trailing twelve-month return on equity of 21.10% and a net margin of 39.62%. Who are POINT Biopharma Global's major shareholders? POINT Biopharma Global's stock is owned by many different retail and institutional investors. Top institutional shareholders include Clear Street Markets LLC (0.00%), Perceptive Advisors LLC (0.00%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Allan C Silber, Bvf Partners L P/Il, Joe A Mccann, Jonathan R Goodman, Neil E Fleshner and Yael Margolin. View institutional ownership trends. This page (NASDAQ:PNT) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss RatingsIs AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding POINT Biopharma Global Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.